{
"instance": {
"blgo20220630_10q.htm": {
"axisCustom": 0,
"axisStandard": 27,
"contextCount": 370,
"dts": {
"calculationLink": {
"local": [
"blgo-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"blgo-20220630_def.xml"
]
},
"inline": {
"local": [
"blgo20220630_10q.htm"
]
},
"labelLink": {
"local": [
"blgo-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"blgo-20220630_pre.xml"
]
},
"schema": {
"local": [
"blgo-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
"https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
"https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
"https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
"https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
]
}
},
"elementCount": 456,
"entityCount": 1,
"hidden": {
"http://biolargo.com/20220630": 8,
"http://fasb.org/us-gaap/2022": 51,
"http://xbrl.sec.gov/dei/2022": 6,
"total": 65
},
"keyCustom": 52,
"keyStandard": 219,
"memberCustom": 56,
"memberStandard": 25,
"nsprefix": "blgo",
"nsuri": "http://biolargo.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "000 - Document - Document And Entity Information",
"role": "http://biolargo.com/20220630/role/statement-document-and-entity-information",
"shortName": "Document And Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "009 - Disclosure - Note 4 - Debt Obligations",
"role": "http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"shortName": "Note 4 - Debt Obligations",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "010 - Disclosure - Note 5 - Share-based Compensation",
"role": "http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"shortName": "Note 5 - Share-based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "blgo:WarrantsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "011 - Disclosure - Note 6 - Warrants",
"role": "http://biolargo.com/20220630/role/statement-note-6-warrants",
"shortName": "Note 6 - Warrants",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "blgo:WarrantsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "012 - Disclosure - Note 7 - Accounts Payable and Accrued Expenses",
"role": "http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses",
"shortName": "Note 7 - Accounts Payable and Accrued Expenses",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:MinorityInterestDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "013 - Disclosure - Note 8 - Noncontrolling Interest - Clyra Medical",
"role": "http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"shortName": "Note 8 - Noncontrolling Interest - Clyra Medical",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:MinorityInterestDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "014 - Disclosure - Note 9 - Business Segment Information",
"role": "http://biolargo.com/20220630/role/statement-note-9-business-segment-information",
"shortName": "Note 9 - Business Segment Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "015 - Disclosure - Note 10 - Commitments and Contingencies",
"role": "http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies",
"shortName": "Note 10 - Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "016 - Disclosure - Note 11 - Subsequent Events",
"role": "http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"shortName": "Note 11 - Subsequent Events",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConsolidationPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "017 - Disclosure - Significant Accounting Policies (Policies)",
"role": "http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies",
"shortName": "Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConsolidationPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"us-gaap:CashAndCashEquivalentsPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
"shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:CashAndCashEquivalentsPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)",
"role": "http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"shortName": "Consolidated Balance Sheets (Current Period Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"lang": null,
"name": "us-gaap:AccountsReceivableNetCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "019 - Disclosure - Note 4 - Debt Obligations (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables",
"shortName": "Note 4 - Debt Obligations (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "020 - Disclosure - Note 5 - Share-based Compensation (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables",
"shortName": "Note 5 - Share-based Compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"blgo:WarrantsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "021 - Disclosure - Note 6 - Warrants (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-6-warrants-tables",
"shortName": "Note 6 - Warrants (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"blgo:WarrantsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "022 - Disclosure - Note 7 - Accounts Payable and Accrued Expenses (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"shortName": "Note 7 - Accounts Payable and Accrued Expenses (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R24": {
"firstAnchor": {
"ancestors": [
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "023 - Disclosure - Note 8 - Noncontrolling Interest - Clyra Medical (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"shortName": "Note 8 - Noncontrolling Interest - Clyra Medical (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "024 - Disclosure - Note 9 - Business Segment Information (Tables)",
"role": "http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables",
"shortName": "Note 9 - Business Segment Information (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "025 - Disclosure - Note 1 - Business and Organization (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"shortName": "Note 1 - Business and Organization (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R27": {
"firstAnchor": {
"ancestors": [
"span",
"em",
"p",
"us-gaap:ReceivablesPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:InventoryPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2021-12-31",
"decimals": "INF",
"lang": null,
"name": "us-gaap:InventoryValuationReserves",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "027 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details",
"shortName": "Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"us-gaap:CashAndCashEquivalentsPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_ConsolidatedEntitiesAxis-ParentCompanyMember",
"decimals": "-3",
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"us-gaap:ConcentrationRiskCreditRisk",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ConcentrationRiskPercentage1",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "028 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details",
"shortName": "Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"us-gaap:ConcentrationRiskCreditRisk",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember",
"decimals": "2",
"first": true,
"lang": null,
"name": "us-gaap:ConcentrationRiskPercentage1",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": null,
"groupType": "statement",
"isDefault": "false",
"longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
"role": "http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
"subGroupType": "parenthetical",
"uniqueAnchor": null
},
"R30": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"us-gaap:InventoryPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "029 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Inventory (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details",
"shortName": "Note 2 - Summary of Significant Accounting Policies - Inventory (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"us-gaap:InventoryPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30_PlanNameAxis-NonPlanMember",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "030 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"shortName": "Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30_PlanNameAxis-NonPlanMember",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "-4",
"first": true,
"lang": null,
"name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "031 - Disclosure - Note 3 - Sale of Stock for Cash (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"shortName": "Note 3 - Sale of Stock for Cash (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R33": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:InterestExpenseDebt",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "032 - Disclosure - Note 4 - Debt Obligations (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"shortName": "Note 4 - Debt Obligations (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:InterestExpenseDebt",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfDebtTableTextBlock",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "033 - Disclosure - Note 4 - Debt Obligations - Schedule of Debt (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"shortName": "Note 4 - Debt Obligations - Schedule of Debt (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfDebtTableTextBlock",
"us-gaap:DebtDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "034 - Disclosure - Note 5 - Share-based Compensation (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"shortName": "Note 5 - Share-based Compensation (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2018-06-22_2018-06-22_PlanNameAxis-EquityIncentivePlan2018Member",
"decimals": null,
"lang": "en-US",
"name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2021-12-31_PlanNameAxis-EquityIncentivePlan2018Member",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "035 - Disclosure - Note 5 - Share-based Compensation - Stock Options (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"shortName": "Note 5 - Share-based Compensation - Stock Options (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2021-12-31_PlanNameAxis-EquityIncentivePlan2018Member",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"p",
"blgo:WarrantsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_ClassOfWarrantOrRightAxis-SixMonthWarrantsInConnectionWithThe2020UnitOfferingMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "036 - Disclosure - Note 6 - Warrants (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"shortName": "Note 6 - Warrants (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"blgo:WarrantsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_ClassOfWarrantOrRightAxis-SixMonthWarrantsInConnectionWithThe2020UnitOfferingMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"blgo:WarrantsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2021-12-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "037 - Disclosure - Note 6 - Warrants - Warrants Outstanding (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"shortName": "Note 6 - Warrants - Warrants Outstanding (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"blgo:WarrantsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2021-12-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_ConsolidationItemsAxis-CorporateNonSegmentMember",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "038 - Disclosure - Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"shortName": "Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_ConsolidationItemsAxis-CorporateNonSegmentMember",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
"role": "http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "-3",
"lang": null,
"name": "us-gaap:GrossProfit",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtConversionOriginalDebtAmount1",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "039 - Disclosure - Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual",
"shortName": "Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30_LegalEntityAxis-ClyraMedicalMember",
"decimals": "-3",
"lang": null,
"name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"b",
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_LegalEntityAxis-ClyraMedicalTechnologyIncMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "040 - Disclosure - Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"shortName": "Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"b",
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfOtherOwnershipInterestsTextBlock",
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_LegalEntityAxis-ClyraMedicalTechnologyIncMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_LegalEntityAxis-ClyraMedicalMember",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "041 - Disclosure - Note 8 - Noncontrolling Interest - Summary of Accounts Payable and Accrued Expenses (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"shortName": "Note 8 - Noncontrolling Interest - Summary of Accounts Payable and Accrued Expenses (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"us-gaap:MinorityInterestDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-06-30_LegalEntityAxis-ClyraMedicalMember",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:NumberOfOperatingSegments",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "042 - Disclosure - Note 9 - Business Segment Information (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-9-business-segment-information-details-textual",
"shortName": "Note 9 - Business Segment Information (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:NumberOfOperatingSegments",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-04-01_2022-06-30",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "043 - Disclosure - Note 9 - Business Segment Information - Segment Information (Details)",
"role": "http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details",
"shortName": "Note 9 - Business Segment Information - Segment Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"ix:continuation",
"us-gaap:SegmentReportingDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2021-12-31",
"decimals": "-3",
"lang": null,
"name": "blgo:FinitelivedTangibleAssetsNet",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "044 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual",
"shortName": "Note 10 - Commitments and Contingencies (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "-4",
"first": true,
"lang": null,
"name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "045 - Disclosure - Note 11 - Subsequent Events (Details Textual)",
"role": "http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"shortName": "Note 11 - Subsequent Events (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:SubsequentEventsTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2022-08-03_ClassOfWarrantOrRightAxis-WarrantsExpiringSixMonthAfterInvestmentDateMember_SubsequentEventTypeAxis-SubsequentEventMember",
"decimals": "INF",
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesIssued",
"reportCount": 1,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
"role": "http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember",
"decimals": "INF",
"lang": null,
"name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "005 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
"role": "http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"shortName": "Consolidated Statements of Cash Flows (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ShareBasedCompensation",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "006 - Disclosure - Note 1 - Business and Organization",
"role": "http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"shortName": "Note 1 - Business and Organization",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
"role": "http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"shortName": "Note 2 - Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "blgo:StockPurchaseAgreementTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "008 - Disclosure - Note 3 - Sale of Stock for Cash",
"role": "http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"shortName": "Note 3 - Sale of Stock for Cash",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "blgo20220630_10q.htm",
"contextRef": "d_2022-01-01_2022-06-30",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "blgo:StockPurchaseAgreementTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 86,
"tag": {
"blgo_AdjustmentsToAdditionalPaidInCapitalWarrantsAndConversionFeatureIssued": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants and conversion feature on convertible debt.",
"label": "Warrants and conversion feature issued as discount on convertible note payable"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsAndConversionFeatureIssued",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_AllocationOfStockOptionExpenseWithinNoncontrollingInterest": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of stock option expense allocated within noncontrolling itnerest.",
"label": "Allocation of noncontrolling interest"
}
}
},
"localname": "AllocationOfStockOptionExpenseWithinNoncontrollingInterest",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_BLESTMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related to the entity BLEST.",
"label": "BLEST [Member]"
}
}
},
"localname": "BLESTMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_BeachHouseConsultingLlcMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information related to Beach House Consulting, LLC.",
"label": "Beach House Consulting, LLC [Member]"
}
}
},
"localname": "BeachHouseConsultingLlcMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_BiolargoEngineeringScienceTechnologiesLLCMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding the entity BioLargo Engineering, Science & Technologies, LLC.",
"label": "BioLargo Engineering, Science & Technologies, LLC [Member]"
}
}
},
"localname": "BiolargoEngineeringScienceTechnologiesLLCMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_BiolargoMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related to the entity Biolargo.",
"label": "Biolargo [Member]"
}
}
},
"localname": "BiolargoMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details"
],
"xbrltype": "domainItemType"
},
"blgo_BiolargoWaterMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information pertaining to the operating segment BioLargo Water",
"label": "BioLargo Water [Member]"
}
}
},
"localname": "BiolargoWaterMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_BktAndTomorrowWaterMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents BKT and Tomorrow Water.",
"label": "BKT and Tomorrow Water [Member]"
}
}
},
"localname": "BktAndTomorrowWaterMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_BoardOfDirectorsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information related to the company's board of directors.",
"label": "Board Of Directors [Member]"
}
}
},
"localname": "BoardOfDirectorsMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_CFOAndPresidentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the CFO and President.",
"label": "CFO and President [Member]"
}
}
},
"localname": "CFOAndPresidentMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_CanadianGovernmentGrantsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The Canadian National Research Institute \u2013 Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC).",
"label": "Canadian Government Grants [Member]"
}
}
},
"localname": "CanadianGovernmentGrantsMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_ClassOfWarrantOrRightAggregateValueOfWarrantsOrRights": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents aggregate value of warrants or rights.",
"label": "Balance, aggregate intrinsic value"
}
}
},
"localname": "ClassOfWarrantOrRightAggregateValueOfWarrantsOrRights",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "monetaryItemType"
},
"blgo_ClassOfWarrantOrRightExpiredDuringPeriod": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of warrants or rights expired during period.",
"label": "blgo_ClassOfWarrantOrRightExpiredDuringPeriod",
"negatedLabel": "Expired (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightExpiredDuringPeriod",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "sharesItemType"
},
"blgo_ClassOfWarrantOrRightIssuedDuringPeriod": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of warrants or rights issued during period.",
"label": "Issued (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "sharesItemType"
},
"blgo_ClyraMedicalCommonStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information related to Clyra Medical common stock.",
"label": "Clyra Medical Common Stock [Member]"
}
}
},
"localname": "ClyraMedicalCommonStockMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "domainItemType"
},
"blgo_ClyraMedicalMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related to the entity Clyra Medical.",
"label": "Clyra Medical [Member]"
}
}
},
"localname": "ClyraMedicalMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_ClyraMedicalTechnologiesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related to the entity Clyra Medical Technologies.",
"label": "Clyra Medical Technologies [Member]"
}
}
},
"localname": "ClyraMedicalTechnologiesMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_ClyraMedicalTechnologyIncMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the Clyra medical technology inc.",
"label": "Clyra Medical Technology Inc [Member]"
}
}
},
"localname": "ClyraMedicalTechnologyIncMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details"
],
"xbrltype": "domainItemType"
},
"blgo_ClyraSegmentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information pertaining to the operating segment of Clyra.",
"label": "Clyra Segment [Member]"
}
}
},
"localname": "ClyraSegmentMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_CommonStockIssuedForAccruedInterestDueOnPromissoryNoteMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents common stock issued for accrued interest due on promissory note.",
"label": "Common Stock Issued for Accrued Interest Due on Promissory Note [Member]"
}
}
},
"localname": "CommonStockIssuedForAccruedInterestDueOnPromissoryNoteMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_ConsultantsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the Consultants.",
"label": "Consultants [Member]"
}
}
},
"localname": "ConsultantsMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_ConsultingServicesMonthlyPayment": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of monthly payments towards a consultant.",
"label": "blgo_ConsultingServicesMonthlyPayment",
"terseLabel": "Consulting Services, Monthly Payment"
}
}
},
"localname": "ConsultingServicesMonthlyPayment",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_ConsultingServicesPeriodOfServices": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The period of time in which the consultant will be providing consulting services.",
"label": "blgo_ConsultingServicesPeriodOfServices",
"terseLabel": "Consulting Services, Period of Services (Year)"
}
}
},
"localname": "ConsultingServicesPeriodOfServices",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "durationItemType"
},
"blgo_ConsultingServicesThreeConsecutiveMonthAverageRevenueThresholdForConsultingFeesToAccrue": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Average amount of revenue needed for three consecutive months for consulting service fees to become accrued.",
"label": "blgo_ConsultingServicesThreeConsecutiveMonthAverageRevenueThresholdForConsultingFeesToAccrue",
"terseLabel": "Consulting Services, Three Consecutive Month Average Revenue Threshold for Consulting Fees to Accrue"
}
}
},
"localname": "ConsultingServicesThreeConsecutiveMonthAverageRevenueThresholdForConsultingFeesToAccrue",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_ContractWithCustomerLiabilityRevenueRecognizedDuringPeriod": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized during period including amounts previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.)",
"label": "blgo_ContractWithCustomerLiabilityRevenueRecognizedDuringPeriod",
"terseLabel": "Contract With Customer, Liability, Revenue Recognized During Period"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognizedDuringPeriod",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_ConversionOfWorkingCapitalAdvancesIntoClyraMedicalCommonStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents Conversion of Working Capital Advances into Clyra Medical Common Stock.",
"label": "Conversion of Working Capital Advances into Clyra Medical Common Stock [Member]"
}
}
},
"localname": "ConversionOfWorkingCapitalAdvancesIntoClyraMedicalCommonStockMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_ConvertibleNoteMaturingOnMarch12023Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Convertible Note, Maturing On March 1, 2023.",
"label": "Convertible Note, Maturing On March 1, 2023 [Member]"
}
}
},
"localname": "ConvertibleNoteMaturingOnMarch12023Member",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "domainItemType"
},
"blgo_CorporateOfficeLeaseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information related to the corporate office lease.",
"label": "Corporate Office Lease [Member]"
}
}
},
"localname": "CorporateOfficeLeaseMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer A.",
"label": "Customer A [Member]"
}
}
},
"localname": "CustomerAMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerBMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer B.",
"label": "Customer B [Member]"
}
}
},
"localname": "CustomerBMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerCMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer C.",
"label": "Customer C [Member]"
}
}
},
"localname": "CustomerCMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerDMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer D.",
"label": "Customer D [Member]"
}
}
},
"localname": "CustomerDMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerEMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer E.",
"label": "Customer E [Member]"
}
}
},
"localname": "CustomerEMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerFMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer F.",
"label": "Customer F [Member]"
}
}
},
"localname": "CustomerFMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerGMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer G.",
"label": "Customer G [Member]"
}
}
},
"localname": "CustomerGMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerHMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding customer H.",
"label": "Customer H [Member]"
}
}
},
"localname": "CustomerHMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_CustomerIMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents customer I.",
"label": "Customer I [Member]"
}
}
},
"localname": "CustomerIMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"blgo_DebtInstrumentConvertibleConversionPercentage": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The percentage of lowest price per share of shares sold for conversion price of the debt instrument.",
"label": "blgo_DebtInstrumentConvertibleConversionPercentage",
"terseLabel": "Debt Instrument, Convertible, Conversion Percentage"
}
}
},
"localname": "DebtInstrumentConvertibleConversionPercentage",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"blgo_DebtInstrumentConvertibleSaleOfStockAmount": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of sale of stock to trigger conversion under the debt instrument.",
"label": "blgo_DebtInstrumentConvertibleSaleOfStockAmount",
"terseLabel": "Debt Instrument, Convertible, Sale of Stock Amount"
}
}
},
"localname": "DebtInstrumentConvertibleSaleOfStockAmount",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_DeemedDividendForTheChangeInAccountingForDerivativeLiability": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount charged for deemed dividends for the change in an accounting for a derivative liability.",
"label": "Net (loss) income attributable to noncontrolling interest"
}
}
},
"localname": "DeemedDividendForTheChangeInAccountingForDerivativeLiability",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_EconomicInjuryDisasterLoanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related to debt under the SBA's Economic Injury Disaster Loan program.",
"label": "Economic Injury Disaster Loan [Member]"
}
}
},
"localname": "EconomicInjuryDisasterLoanMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "domainItemType"
},
"blgo_EmployeesAndConsultantsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Employees and Consultants.",
"label": "Employees and Consultants [Member]"
}
}
},
"localname": "EmployeesAndConsultantsMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_EmployeesConsultationsOfficersAndDirectorsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information related to employees, consultations, officers, and directors.",
"label": "Employees, Consultations, Officers, and Directors [Member]"
}
}
},
"localname": "EmployeesConsultationsOfficersAndDirectorsMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_EmployeesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the employees.",
"label": "Employees [Member]"
}
}
},
"localname": "EmployeesMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_EntitiesExcludingPartiallyOwnedSubsidiaryMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents all the consolidated entities, excluding partially owned subsidiary.",
"label": "Entities, Excluding Partially Owned Subsidiary [Member]"
}
}
},
"localname": "EntitiesExcludingPartiallyOwnedSubsidiaryMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "domainItemType"
},
"blgo_EquityIncentivePlan2018Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertaining to 2018 equity incentive plan.",
"label": "2018 Equity Incentive Plan [Member]"
}
}
},
"localname": "EquityIncentivePlan2018Member",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "domainItemType"
},
"blgo_FinitelivedTangibleAssetsNet": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after amortization of assets which have physical substance with a finite life.",
"label": "blgo_FinitelivedTangibleAssetsNet",
"terseLabel": "Tangible assets"
}
}
},
"localname": "FinitelivedTangibleAssetsNet",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"blgo_FiveyearWarrantsInConnectionWithThe2020UnitOfferingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to five-year warrants issued in connection with the 2020 Unit Offering.",
"label": "Five-year Warrants in Connection With the 2020 Unit Offering [Member]"
}
}
},
"localname": "FiveyearWarrantsInConnectionWithThe2020UnitOfferingMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_GainFromPPPLoanForgiveness": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
},
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the amount of gain recognized during the period from Paycheck Protection Program (CARES Act) loan forgiveness.",
"label": "PPP loan forgiveness",
"negatedLabel": "PPP loan forgiveness"
}
}
},
"localname": "GainFromPPPLoanForgiveness",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_GovernmentGrantsPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The disclosure of policies relating to government grants.",
"label": "Government Grants [Policy Text Block]"
}
}
},
"localname": "GovernmentGrantsPolicyTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"blgo_GrantTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Period for grants earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.",
"label": "blgo_GrantTerm",
"terseLabel": "Grant Term (Month)"
}
}
},
"localname": "GrantTerm",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "durationItemType"
},
"blgo_IncreaseDecreaseInLiabilityForCustomerDeposits": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the increase (decrease) in the liability for customer deposits during the period.",
"label": "blgo_IncreaseDecreaseInLiabilityForCustomerDeposits",
"terseLabel": "Customer deposits"
}
}
},
"localname": "IncreaseDecreaseInLiabilityForCustomerDeposits",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_InventoryLineOfCreditMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information related to the inventory line of credit.",
"label": "Inventory Line of Credit [Member]"
}
}
},
"localname": "InventoryLineOfCreditMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_InvestmentInSouthKoreanJointVentureMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information related to investment in South Korean joint venture.",
"label": "Investment in South Korean Joint Venture [Member]"
}
}
},
"localname": "InvestmentInSouthKoreanJointVentureMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_IssuanceOfStockForPaymentOfInterest": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of stock issued for on lieu of payment of interest.",
"label": "Common stock issued for interest"
}
}
},
"localname": "IssuanceOfStockForPaymentOfInterest",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_LesseeOperatingLeaseOptionToExtendTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease option to extend, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "blgo_LesseeOperatingLeaseOptionToExtendTerm",
"terseLabel": "Lessee, Operating Lease, Option to Extend Term (Year)"
}
}
},
"localname": "LesseeOperatingLeaseOptionToExtendTerm",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "durationItemType"
},
"blgo_LiabilityForCustomerDepositsCurrent": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the current liability for customer deposits as of the balance sheet date.",
"label": "Customer deposits"
}
}
},
"localname": "LiabilityForCustomerDepositsCurrent",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_LincolnParkCapitalFundLLCMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Refers to information regarding the entity Lincoln Park Capital Fund, LLC.",
"label": "Lincoln Park Capital Fund, LLC [Member]"
}
}
},
"localname": "LincolnParkCapitalFundLLCMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_LineOfCreditFacilityCovenantAdditionalDrawsMaximumPercentageOfTotalPrincipalOutstandingAllowed": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum percentage of the total principal outstanding allowed for additional draws if certain covenant requirements are met under the line of credit agreement.",
"label": "blgo_LineOfCreditFacilityCovenantAdditionalDrawsMaximumPercentageOfTotalPrincipalOutstandingAllowed",
"terseLabel": "Line of Credit Facility, Covenant, Additional Draws, Maximum Percentage of Total Principal Outstanding Allowed"
}
}
},
"localname": "LineOfCreditFacilityCovenantAdditionalDrawsMaximumPercentageOfTotalPrincipalOutstandingAllowed",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"blgo_LineOfCreditFacilityCovenantAdditionalDrawsMinimumAmountAllowed": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The minimum amount allowed for additional draws if certain covenant requirements are met under the line of credit agreement.",
"label": "blgo_LineOfCreditFacilityCovenantAdditionalDrawsMinimumAmountAllowed",
"terseLabel": "Line of Credit Facility, Covenant, Additional Draws, Minimum Amount Allowed"
}
}
},
"localname": "LineOfCreditFacilityCovenantAdditionalDrawsMinimumAmountAllowed",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_LineOfCreditFacilityMonthlyPercentageOfGrossProductSalesRequiredToBeUsedAsPaymentOfDebtAfterTheFirst180Days": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The monthly percentage of gross product sales required to be used as payment of debt after the first 180 days under the line of credit agreement.",
"label": "blgo_LineOfCreditFacilityMonthlyPercentageOfGrossProductSalesRequiredToBeUsedAsPaymentOfDebtAfterTheFirst180Days",
"terseLabel": "Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt after the First 180 Days"
}
}
},
"localname": "LineOfCreditFacilityMonthlyPercentageOfGrossProductSalesRequiredToBeUsedAsPaymentOfDebtAfterTheFirst180Days",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"blgo_NonCashTransactionsPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Accounting policy disclosure for non cash transactions.",
"label": "Non Cash Transactions [Policy Text Block]"
}
}
},
"localname": "NonCashTransactionsPolicyTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"blgo_NonPlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the absence of a plan.",
"label": "Non Plan [Member]"
}
}
},
"localname": "NonPlanMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "domainItemType"
},
"blgo_NonoperatingIncomeGrantIncome": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of nonoperating income from grants.",
"label": "Grant income"
}
}
},
"localname": "NonoperatingIncomeGrantIncome",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_NoteToFinancialStatementDetailsTextual": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note To Financial Statement Details Textual"
}
}
},
"localname": "NoteToFinancialStatementDetailsTextual",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_NotesToFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Notes To Financial Statements [Abstract]"
}
}
},
"localname": "NotesToFinancialStatementsAbstract",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_NumberOfGrantsReceived": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants received.",
"label": "blgo_NumberOfGrantsReceived",
"terseLabel": "Number of Grants Received"
}
}
},
"localname": "NumberOfGrantsReceived",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "integerItemType"
},
"blgo_NumberOfWhollyOwnedSubsidiaries": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of wholly-owned subsidiaries operated by the company.",
"label": "blgo_NumberOfWhollyOwnedSubsidiaries",
"terseLabel": "Number of Wholly-Owned Subsidiaries"
}
}
},
"localname": "NumberOfWhollyOwnedSubsidiaries",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual"
],
"xbrltype": "pureItemType"
},
"blgo_ONMMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related to ONM.",
"label": "ONM [Member]"
}
}
},
"localname": "ONMMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_OakRidgeTennesseeFacilityLeaseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information related to the Oak Ridge, Tennessee facility.",
"label": "Oak Ridge, Tennessee Facility Lease [Member]"
}
}
},
"localname": "OakRidgeTennesseeFacilityLeaseMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_OdinCoLtdMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents Odin Co. Ltd.",
"label": "Odin Co Ltd [Member]"
}
}
},
"localname": "OdinCoLtdMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_OdorNoMoreMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information pertaining to the operating segment of Odor-No-More.",
"label": "Odor-No-More [Member]"
}
}
},
"localname": "OdorNoMoreMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"blgo_OtherAssetsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for assets classified as other.",
"label": "Other Assets, Policy [Policy Text Block]"
}
}
},
"localname": "OtherAssetsPolicyPolicyTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"blgo_OtherMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents entities classified as other.",
"label": "Other [Member]"
}
}
},
"localname": "OtherMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details"
],
"xbrltype": "domainItemType"
},
"blgo_PartiallyOwnedSubsidiaryMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the partially owned subsidiary.",
"label": "Partially Owned Subsidiary [Member]"
}
}
},
"localname": "PartiallyOwnedSubsidiaryMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "domainItemType"
},
"blgo_PaycheckProtectionProgramCaresActMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.",
"label": "Paycheck Protection Program CARES Act [Member]"
}
}
},
"localname": "PaycheckProtectionProgramCaresActMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "domainItemType"
},
"blgo_PriceRangeWarrantsExpired": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the price of warrants that expired during the period.",
"label": "Expired, price range (in dollars per share)"
}
}
},
"localname": "PriceRangeWarrantsExpired",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "perShareItemType"
},
"blgo_PriceRangeWarrantsIssued": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the price of warrants that were issued during the period.",
"label": "Granted, price range (in dollars per share)"
}
}
},
"localname": "PriceRangeWarrantsIssued",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "perShareItemType"
},
"blgo_PriceRangeWarrantsOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the price of warrants outstanding.",
"label": "blgo_PriceRangeWarrantsOutstanding",
"periodEndLabel": "Balance, outstanding, price range (in dollars per share)",
"periodStartLabel": "Balance, outstanding, price range (in dollars per share)"
}
}
},
"localname": "PriceRangeWarrantsOutstanding",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "perShareItemType"
},
"blgo_ProfitLossIncludingDeemedDividendsForTheChangeAccountingForDerivativeLiability": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest and the deemed dividends for the change of accounting for derivative liability.",
"label": "blgo_ProfitLossIncludingDeemedDividendsForTheChangeAccountingForDerivativeLiability",
"totalLabel": "Net loss"
}
}
},
"localname": "ProfitLossIncludingDeemedDividendsForTheChangeAccountingForDerivativeLiability",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_SanatioMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents Sanatio Capital LLC.",
"label": "Sanatio [Member]"
}
}
},
"localname": "SanatioMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details"
],
"xbrltype": "domainItemType"
},
"blgo_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The discount rate assumption that is used in valuing an option on its own shares.",
"label": "blgo_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsDiscountRate",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"blgo_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAuthorizedPerYear": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of additional shares authorized per year for issuance under an established share-based compensation plan.",
"label": "blgo_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAuthorizedPerYear",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesAuthorizedPerYear",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"blgo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsPerMonthGross": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted per month.",
"label": "blgo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsPerMonthGross",
"terseLabel": "Share-based Compensation Arrangement By Share-based Payment Award, Options Grants Per Month, Gross (in shares)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsPerMonthGross",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"blgo_SixMonthWarrantsInConnectionWithThe2020UnitOfferingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to six-month warrants issued in connection with the 2020 Unit Offering.",
"label": "Six-month Warrants in Connection With the 2020 Unit Offering [Member]"
}
}
},
"localname": "SixMonthWarrantsInConnectionWithThe2020UnitOfferingMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_StockIssuedDuringPeriodSharePaidForInterest": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares issued as payment of interest.",
"label": "Issuance of common stock for interest (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharePaidForInterest",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "sharesItemType"
},
"blgo_StockIssuedDuringPeriodSharesCommitmentFee": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of commitment fee stock issued during the period.",
"label": "blgo_StockIssuedDuringPeriodSharesCommitmentFee",
"terseLabel": "Stock Issued During Period, Shares, Commitment Fee (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesCommitmentFee",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "sharesItemType"
},
"blgo_StockIssuedDuringPeriodValueCommitmentFee": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of commitment fee stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "blgo_StockIssuedDuringPeriodValueCommitmentFee",
"terseLabel": "Stock Issued During Period, Value, Commitment Fee"
}
}
},
"localname": "StockIssuedDuringPeriodValueCommitmentFee",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_StockIssuedDuringPeriodValuePaidForInterest": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued as payment for interest.",
"label": "Issuance of common stock for interest"
}
}
},
"localname": "StockIssuedDuringPeriodValuePaidForInterest",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_StockOptionsExercisePriceRange": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock options exercise price range.",
"label": "blgo_StockOptionsExercisePriceRange",
"periodEndLabel": "Exercise price per share, balance (in dollars per share)",
"periodStartLabel": "Exercise price per share, balance (in dollars per share)"
}
}
},
"localname": "StockOptionsExercisePriceRange",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"blgo_StockOptionsGrantedExercisePriceRange": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the exercise price range of stock options granted.",
"label": "Exercise price per share, granted (in dollars per share)"
}
}
},
"localname": "StockOptionsGrantedExercisePriceRange",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"blgo_StockOptionsNonvestedExercisePriceRange": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock options non-vested exercise price range.",
"label": "Exercise price per share, Non-vested (in dollars per share)"
}
}
},
"localname": "StockOptionsNonvestedExercisePriceRange",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"blgo_StockOptionsVestedAndOutstandingExercisePriceRange": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The exercise price range for stock options vested and outstanding.",
"label": "Exercise price per share, Vested (in dollars per share)"
}
}
},
"localname": "StockOptionsVestedAndOutstandingExercisePriceRange",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"blgo_StockPurchaseAgreementTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The textual disclosure of information pertaining to a stock purchase agreement.",
"label": "Stock Purchase Agreement [Text Block]"
}
}
},
"localname": "StockPurchaseAgreementTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash"
],
"xbrltype": "textBlockItemType"
},
"blgo_StockholdersEquityAllocationOfNoncontrollingInterestFromSubsidiarysEquityIssuance": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "This element represents movements included in the statement of changes in stockholders' equity in connection with the allocation of noncontrolling interest from subsidiary's equity issuance.",
"label": "Noncontrolling interest allocation"
}
}
},
"localname": "StockholdersEquityAllocationOfNoncontrollingInterestFromSubsidiarysEquityIssuance",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_TangibleAndIntangibleAssetsRightofuseAssetsAndEquityMethodInvestmentTotal": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total amount of tangible and intangible assets, right-of-use assets and equity method investment.",
"label": "blgo_TangibleAndIntangibleAssetsRightofuseAssetsAndEquityMethodInvestmentTotal",
"verboseLabel": "Total"
}
}
},
"localname": "TangibleAndIntangibleAssetsRightofuseAssetsAndEquityMethodInvestmentTotal",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"blgo_TaxCreditIncome": {
"auth_ref": [
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the amount of tax credit income during the period.",
"label": "Tax credit"
}
}
},
"localname": "TaxCreditIncome",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"blgo_TaxCreditsPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for tax credits.",
"label": "Tax Credits [Policy Text Block]"
}
}
},
"localname": "TaxCreditsPolicyTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"blgo_TermExtension": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Term extension, in years.",
"label": "blgo_TermExtension",
"terseLabel": "Term Extension (Year)"
}
}
},
"localname": "TermExtension",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "durationItemType"
},
"blgo_The2007EquityIncentivePlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to the Company's 2007 Equity Incentive Plan.",
"label": "The 2007 Equity Incentive Plan [Member]"
}
}
},
"localname": "The2007EquityIncentivePlanMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "domainItemType"
},
"blgo_The2020UnitOfferingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information regarding the 2020 Unit Offering.",
"label": "The 2020 Unit Offering [Member]"
}
}
},
"localname": "The2020UnitOfferingMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_TomorrowWaterMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents Tomorrow Water.",
"label": "Tomorrow Water [Member]"
}
}
},
"localname": "TomorrowWaterMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_VendorsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The element represents vendors.",
"label": "Vendors [Member]"
}
}
},
"localname": "VendorsMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_VernalBayCapitalGroupLLCMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information related to Vernal Bay Capital Group, LLC.",
"label": "Vernal Bay Capital Group, LLC [Member]"
}
}
},
"localname": "VernalBayCapitalGroupLLCMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_WarrantPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for warrant.",
"label": "Warrant Policy [Policy Text Block]"
}
}
},
"localname": "WarrantPolicyTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"blgo_WarrantsExpiringFiveYearsAfterInvestmentDateMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Warrants Expiring Five Years After Investment Date.",
"label": "Warrants Expiring Five Years After Investment Date [Member]"
}
}
},
"localname": "WarrantsExpiringFiveYearsAfterInvestmentDateMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_WarrantsExpiringSixMonthAfterInvestmentDateMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents warrants expiring six month after investment date.",
"label": "Warrants Expiring Six Month After Investment Date [Member]"
}
}
},
"localname": "WarrantsExpiringSixMonthAfterInvestmentDateMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_WarrantsIssuedWith2020UnitOfferingMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the warrants issued with 2020 unit offering.",
"label": "Warrants Issued with 2020 Unit Offering [Member]"
}
}
},
"localname": "WarrantsIssuedWith2020UnitOfferingMember",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual"
],
"xbrltype": "domainItemType"
},
"blgo_WarrantsTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of notes that entitle the holder to buy stock of the company at a specified price, which is much higher than the stock price at the time of issue.",
"label": "Warrants [Text Block]"
}
}
},
"localname": "WarrantsTextBlock",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants"
],
"xbrltype": "textBlockItemType"
},
"blgo_WorkingCapitalDeficit": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the value of total current assets net of current liabilities as of the balance sheet date.",
"label": "blgo_WorkingCapitalDeficit",
"terseLabel": "Working Capital (Deficit)"
}
}
},
"localname": "WorkingCapitalDeficit",
"nsuri": "http://biolargo.com/20220630",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual"
],
"xbrltype": "monetaryItemType"
},
"blgo_statement-statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details)"
}
}
},
"localname": "statement-statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-2-summary-of-significant-accounting-policies-inventory-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 2 - Summary of Significant Accounting Policies - Inventory (Details)"
}
}
},
"localname": "statement-statement-note-2-summary-of-significant-accounting-policies-inventory-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)"
}
}
},
"localname": "statement-statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details)"
}
}
},
"localname": "statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 2 - Summary of Significant Accounting Policies"
}
}
},
"localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-4-debt-obligations-schedule-of-debt-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Debt Obligations - Schedule of Debt (Details)"
}
}
},
"localname": "statement-statement-note-4-debt-obligations-schedule-of-debt-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-4-debt-obligations-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Debt Obligations"
}
}
},
"localname": "statement-statement-note-4-debt-obligations-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-5-sharebased-compensation-stock-options-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 5 - Share-based Compensation - Stock Options (Details)"
}
}
},
"localname": "statement-statement-note-5-sharebased-compensation-stock-options-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-5-sharebased-compensation-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 5 - Share-based Compensation"
}
}
},
"localname": "statement-statement-note-5-sharebased-compensation-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-6-warrants-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 6 - Warrants"
}
}
},
"localname": "statement-statement-note-6-warrants-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-6-warrants-warrants-outstanding-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 6 - Warrants - Warrants Outstanding (Details)"
}
}
},
"localname": "statement-statement-note-6-warrants-warrants-outstanding-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)"
}
}
},
"localname": "statement-statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-7-accounts-payable-and-accrued-expenses-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 7 - Accounts Payable and Accrued Expenses"
}
}
},
"localname": "statement-statement-note-7-accounts-payable-and-accrued-expenses-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details)"
}
}
},
"localname": "statement-statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-8-noncontrolling-interest-clyra-medical-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Noncontrolling Interest - Clyra Medical"
}
}
},
"localname": "statement-statement-note-8-noncontrolling-interest-clyra-medical-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Noncontrolling Interest - Summary of Accounts Payable and Accrued Expenses (Details)"
}
}
},
"localname": "statement-statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-9-business-segment-information-segment-information-details": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 9 - Business Segment Information - Segment Information (Details)"
}
}
},
"localname": "statement-statement-note-9-business-segment-information-segment-information-details",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-note-9-business-segment-information-tables": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Note 9 - Business Segment Information"
}
}
},
"localname": "statement-statement-note-9-business-segment-information-tables",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"blgo_statement-statement-significant-accounting-policies-policies": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Significant Accounting Policies"
}
}
},
"localname": "statement-statement-significant-accounting-policies-policies",
"nsuri": "http://biolargo.com/20220630",
"xbrltype": "stringItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentInformationLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Document Information [Line Items]"
}
}
},
"localname": "DocumentInformationLineItems",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "stringItemType"
},
"dei_DocumentInformationTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
"label": "Document Information [Table]"
}
}
},
"localname": "DocumentInformationTable",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r506"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r507"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
"label": "Entity [Domain]"
}
}
},
"localname": "EntityDomain",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-document-and-entity-information",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables",
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "domainItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r508"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r505"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "employerIdItemType"
},
"dei_LegalEntityAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The set of legal entities associated with a report.",
"label": "Legal Entity [Axis]"
}
}
},
"localname": "LegalEntityAxis",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-document-and-entity-information",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables",
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r504"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "securityTitleItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-document-and-entity-information"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_ChiefFinancialOfficerMember": {
"auth_ref": [
"r189"
],
"lang": {
"en-us": {
"role": {
"label": "Chief Financial Officer [Member]"
}
}
},
"localname": "ChiefFinancialOfficerMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidatedEntitiesAxis": {
"auth_ref": [
"r111",
"r247",
"r252",
"r260",
"r386",
"r387",
"r393",
"r394",
"r437",
"r500"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Axis]"
}
}
},
"localname": "ConsolidatedEntitiesAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidatedEntitiesDomain": {
"auth_ref": [
"r111",
"r247",
"r252",
"r260",
"r386",
"r387",
"r393",
"r394",
"r437",
"r500"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Domain]"
}
}
},
"localname": "ConsolidatedEntitiesDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidationEliminationsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation, Eliminations [Member]"
}
}
},
"localname": "ConsolidationEliminationsMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidationItemsAxis": {
"auth_ref": [
"r111",
"r157",
"r170",
"r171",
"r172",
"r173",
"r175",
"r177",
"r181",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r254",
"r255",
"r257",
"r259",
"r260"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Axis]"
}
}
},
"localname": "ConsolidationItemsAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidationItemsDomain": {
"auth_ref": [
"r111",
"r157",
"r170",
"r171",
"r172",
"r173",
"r175",
"r177",
"r181",
"r247",
"r248",
"r249",
"r250",
"r251",
"r252",
"r254",
"r255",
"r257",
"r259",
"r260"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Domain]"
}
}
},
"localname": "ConsolidationItemsDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"srt_CounterpartyNameAxis": {
"auth_ref": [
"r52",
"r54",
"r109",
"r110",
"r266",
"r299"
],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Axis]"
}
}
},
"localname": "CounterpartyNameAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"srt_EquityMethodInvesteeNameDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Investment, Name [Domain]"
}
}
},
"localname": "EquityMethodInvesteeNameDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"srt_MajorCustomersAxis": {
"auth_ref": [
"r187",
"r318",
"r321",
"r489"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Axis]"
}
}
},
"localname": "MajorCustomersAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r241",
"r242",
"r243",
"r244",
"r265",
"r298",
"r326",
"r327",
"r444",
"r445",
"r446",
"r447",
"r448",
"r449",
"r450",
"r487",
"r490",
"r501",
"r502"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r241",
"r242",
"r243",
"r244",
"r265",
"r298",
"r326",
"r327",
"r444",
"r445",
"r446",
"r447",
"r448",
"r449",
"r450",
"r487",
"r490",
"r501",
"r502"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_NameOfMajorCustomerDomain": {
"auth_ref": [
"r187",
"r318",
"r321",
"r489"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Domain]"
}
}
},
"localname": "NameOfMajorCustomerDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"srt_OfficerMember": {
"auth_ref": [
"r189"
],
"lang": {
"en-us": {
"role": {
"label": "Officer [Member]"
}
}
},
"localname": "OfficerMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_OwnershipAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Axis]"
}
}
},
"localname": "OwnershipAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"srt_OwnershipDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Domain]"
}
}
},
"localname": "OwnershipDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_ParentCompanyMember": {
"auth_ref": [
"r111"
],
"lang": {
"en-us": {
"role": {
"label": "Parent Company [Member]"
}
}
},
"localname": "ParentCompanyMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r184",
"r242",
"r243",
"r318",
"r320",
"r454",
"r486",
"r488"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r184",
"r242",
"r243",
"r318",
"r320",
"r454",
"r486",
"r488"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r234",
"r241",
"r242",
"r243",
"r244",
"r265",
"r298",
"r325",
"r326",
"r327",
"r358",
"r359",
"r360",
"r444",
"r445",
"r446",
"r447",
"r448",
"r449",
"r450",
"r487",
"r490",
"r501",
"r502"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r234",
"r241",
"r242",
"r243",
"r244",
"r265",
"r298",
"r325",
"r326",
"r327",
"r358",
"r359",
"r360",
"r444",
"r445",
"r446",
"r447",
"r448",
"r449",
"r450",
"r487",
"r490",
"r501",
"r502"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_RepurchaseAgreementCounterpartyNameDomain": {
"auth_ref": [
"r53",
"r54",
"r109",
"r110",
"r266",
"r299"
],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Domain]"
}
}
},
"localname": "RepurchaseAgreementCounterpartyNameDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
"auth_ref": [
"r199"
],
"lang": {
"en-us": {
"role": {
"label": "Investment, Name [Axis]"
}
}
},
"localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r189",
"r436"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Axis]"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Domain]"
}
}
},
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_WeightedAverageMember": {
"auth_ref": [
"r444",
"r446",
"r449",
"r501",
"r502"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average [Member]"
}
}
},
"localname": "WeightedAverageMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
"auth_ref": [
"r42"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
},
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"terseLabel": "Accounts payable and accrued expenses",
"totalLabel": "Total accounts payable and accrued expenses"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r40"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
"label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r39",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": 1.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
},
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": 0.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts payable and accrued expense"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableMember": {
"auth_ref": [
"r498"
],
"lang": {
"en-us": {
"role": {
"documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
"label": "Accounts Receivable [Member]"
}
}
},
"localname": "AccountsReceivableMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r190",
"r191"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts receivable, net of allowance"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r27",
"r57",
"r58",
"r59",
"r475",
"r495",
"r496"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r56",
"r59",
"r66",
"r67",
"r68",
"r113",
"r114",
"r115",
"r392",
"r435",
"r491",
"r492"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r25",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r113",
"r114",
"r115",
"r363",
"r364",
"r365",
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
"label": "Stock option compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r362"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "us-gaap_AllocatedShareBasedCompensationExpense",
"terseLabel": "Share-Based Payment Arrangement, Expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
"auth_ref": [
"r31",
"r193",
"r203"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
"label": "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent",
"terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
"auth_ref": [
"r93",
"r285",
"r294",
"r295",
"r422"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
"label": "Interest expense related to amortization of the discount on convertible notes payable and line of credit"
}
}
},
"localname": "AmortizationOfFinancingCostsAndDiscounts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r16",
"r108",
"r165",
"r172",
"r179",
"r201",
"r247",
"r248",
"r249",
"r251",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r386",
"r393",
"r409",
"r438",
"r440",
"r457",
"r473"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "us-gaap_Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r7",
"r38",
"r108",
"r201",
"r247",
"r248",
"r249",
"r251",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r386",
"r393",
"r409",
"r438",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "us-gaap_AssetsCurrent",
"terseLabel": "Assets, Current, Total",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsNoncurrent": {
"auth_ref": [
"r108",
"r201",
"r247",
"r248",
"r249",
"r251",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r386",
"r393",
"r409",
"r438"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
"label": "us-gaap_AssetsNoncurrent",
"totalLabel": "Total non-current assets"
}
}
},
"localname": "AssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsNoncurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Non-current assets"
}
}
},
"localname": "AssetsNoncurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r330",
"r331",
"r332",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r350",
"r351",
"r353",
"r354",
"r357",
"r358",
"r359",
"r360",
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r5",
"r13",
"r95"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and cash equivalents",
"terseLabel": "Cash and Cash Equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
"auth_ref": [
"r96"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
"label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
}
}
},
"localname": "CashAndCashEquivalentsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"auth_ref": [
"r88",
"r95",
"r101"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"periodEndLabel": "Cash at end of period",
"periodStartLabel": "Cash at beginning of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r88",
"r410"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"totalLabel": "Net change in cash"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Non-cash investing and financing activities"
}
}
},
"localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfWarrantOrRightAxis": {
"auth_ref": [
"r305",
"r329"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of warrant or right issued.",
"label": "Class of Warrant or Right [Axis]"
}
}
},
"localname": "ClassOfWarrantOrRightAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfWarrantOrRightDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
"label": "Class of Warrant or Right [Domain]"
}
}
},
"localname": "ClassOfWarrantOrRightDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
"auth_ref": [
"r301"
],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
"label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
"label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
"terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ClassOfWarrantOrRightOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of warrants or rights outstanding.",
"label": "us-gaap_ClassOfWarrantOrRightOutstanding",
"periodEndLabel": "Balance, outstanding (in shares)",
"periodStartLabel": "Balance, outstanding (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r48",
"r462",
"r480"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "COMMITMENTS AND CONTINGENCIES (Note 10)"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r238",
"r239",
"r240",
"r245",
"r499"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments and Contingencies Disclosure [Text Block]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r113",
"r114",
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r23"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common stock, par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r23"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common stock, shares authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r23"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common stock, shares issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r23",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common stock, $0.00067 Par Value, 400,000,000 Shares Authorized, 268,036,728 and 255,893,726 Shares Issued, at June 30, 2022 and December 31, 2021"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
"auth_ref": [
"r323",
"r324",
"r328",
"r367"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
"label": "Compensation and Employee Benefit Plans [Text Block]"
}
}
},
"localname": "CompensationAndEmployeeBenefitPlansTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r61",
"r63",
"r64",
"r73",
"r466",
"r484"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "us-gaap_ComprehensiveIncomeNetOfTax",
"totalLabel": "Comprehensive loss attributable to common stockholders"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Comprehensive loss:"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
"auth_ref": [
"r61",
"r63",
"r72",
"r383",
"r384",
"r398",
"r465",
"r483"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive loss attributable to noncontrolling interest"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r61",
"r63",
"r71",
"r382",
"r398",
"r464",
"r482"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"totalLabel": "Comprehensive loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"auth_ref": [
"r146",
"r147",
"r187",
"r406",
"r407",
"r498"
],
"lang": {
"en-us": {
"role": {
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
"label": "Concentration Risk Benchmark [Domain]"
}
}
},
"localname": "ConcentrationRiskBenchmarkDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"auth_ref": [
"r146",
"r147",
"r187",
"r406",
"r407",
"r497",
"r498"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by benchmark of concentration risk.",
"label": "Concentration Risk Benchmark [Axis]"
}
}
},
"localname": "ConcentrationRiskByBenchmarkAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"auth_ref": [
"r146",
"r147",
"r187",
"r406",
"r407",
"r497",
"r498"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
"label": "Concentration Risk Type [Axis]"
}
}
},
"localname": "ConcentrationRiskByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskCreditRisk": {
"auth_ref": [
"r141",
"r471"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for credit risk.",
"label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
}
}
},
"localname": "ConcentrationRiskCreditRisk",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConcentrationRiskPercentage1": {
"auth_ref": [
"r146",
"r147",
"r187",
"r406",
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
"label": "Credit concentration"
}
}
},
"localname": "ConcentrationRiskPercentage1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "percentItemType"
},
"us-gaap_ConcentrationRiskTypeDomain": {
"auth_ref": [
"r146",
"r147",
"r187",
"r406",
"r407",
"r498"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
"label": "Concentration Risk Type [Domain]"
}
}
},
"localname": "ConcentrationRiskTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConsolidationPolicyTextBlock": {
"auth_ref": [
"r103",
"r388"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
"label": "Consolidation, Policy [Policy Text Block]"
}
}
},
"localname": "ConsolidationPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerAssetNet": {
"auth_ref": [
"r306",
"r308",
"r319"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
"label": "us-gaap_ContractWithCustomerAssetNet",
"terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total"
}
}
},
"localname": "ContractWithCustomerAssetNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r306",
"r307",
"r319"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "us-gaap_ContractWithCustomerLiability",
"terseLabel": "Contract with Customer, Liability, Total"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r306",
"r307",
"r319"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleNotesPayableCurrent": {
"auth_ref": [
"r44"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
"label": "us-gaap_ConvertibleNotesPayableCurrent",
"terseLabel": "Convertible notes"
}
}
},
"localname": "ConvertibleNotesPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CorporateNonSegmentMember": {
"auth_ref": [
"r170",
"r171",
"r172",
"r173",
"r175",
"r181",
"r183"
],
"lang": {
"en-us": {
"role": {
"documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
"label": "Corporate, Non-Segment [Member]"
}
}
},
"localname": "CorporateNonSegmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r76",
"r454"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "us-gaap_CostOfGoodsAndServicesSold",
"negatedLabel": "Cost of Goods and Services Sold"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfRevenueAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cost of revenue"
}
}
},
"localname": "CostOfRevenueAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Axis]"
}
}
},
"localname": "CreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Domain]"
}
}
},
"localname": "CreditFacilityDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_CustomerConcentrationRiskMember": {
"auth_ref": [
"r145",
"r187"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
"label": "Customer Concentration Risk [Member]"
}
}
},
"localname": "CustomerConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtConversionByUniqueDescriptionAxis": {
"auth_ref": [
"r98",
"r100"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
"label": "Debt Conversion Description [Axis]"
}
}
},
"localname": "DebtConversionByUniqueDescriptionAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
"auth_ref": [
"r98",
"r100"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
"label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1",
"terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)"
}
}
},
"localname": "DebtConversionConvertedInstrumentSharesIssued1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_DebtConversionNameDomain": {
"auth_ref": [
"r98",
"r100"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Debt Conversion, Name [Domain]"
}
}
},
"localname": "DebtConversionNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtConversionOriginalDebtAmount1": {
"auth_ref": [
"r98",
"r100"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Conversion of notes payable to common stock",
"terseLabel": "Debt Conversion, Original Debt, Amount"
}
}
},
"localname": "DebtConversionOriginalDebtAmount1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtCurrent": {
"auth_ref": [
"r19"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of debt and lease obligation, classified as current.",
"label": "us-gaap_DebtCurrent",
"terseLabel": "Total notes payable and line of credit"
}
}
},
"localname": "DebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r106",
"r268",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r279",
"r286",
"r287",
"r288",
"r296"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r17",
"r18",
"r20",
"r107",
"r111",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267",
"r269",
"r275",
"r276",
"r277",
"r278",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r292",
"r293",
"r294",
"r295",
"r423",
"r458",
"r459",
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentConvertibleConversionPrice1": {
"auth_ref": [
"r264",
"r290"
],
"lang": {
"en-us": {
"role": {
"documentation": "The price per share of the conversion feature embedded in the debt instrument.",
"label": "us-gaap_DebtInstrumentConvertibleConversionPrice1",
"terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)"
}
}
},
"localname": "DebtInstrumentConvertibleConversionPrice1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_DebtInstrumentFaceAmount": {
"auth_ref": [
"r262",
"r292",
"r293",
"r421",
"r423",
"r424"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Face (par) amount of debt instrument at time of issuance.",
"label": "us-gaap_DebtInstrumentFaceAmount",
"terseLabel": "Debt Instrument, Face Amount"
}
}
},
"localname": "DebtInstrumentFaceAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r46",
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
"terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r47",
"r107",
"r111",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267",
"r269",
"r275",
"r276",
"r277",
"r278",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r292",
"r293",
"r294",
"r295",
"r423"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_DebtInstrumentTerm",
"terseLabel": "Debt Instrument, Term (Month)"
}
}
},
"localname": "DebtInstrumentTerm",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
"auth_ref": [
"r420",
"r424"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
"label": "us-gaap_DebtInstrumentUnamortizedDiscountCurrent",
"negatedTerseLabel": "Debt discount, net of amortization"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscountCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
"auth_ref": [
"r420",
"r424"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.",
"label": "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent",
"negatedLabel": "Debt discount, net of amortization"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtLongtermAndShorttermCombinedAmount": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
"label": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
"terseLabel": "Total"
}
}
},
"localname": "DebtLongtermAndShorttermCombinedAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r93",
"r228"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation expense"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisclosureTextBlockAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_DisclosureTextBlockAbstract",
"terseLabel": "Notes to Financial Statements"
}
}
},
"localname": "DisclosureTextBlockAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net loss per share attributable to common shareholders:"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r74",
"r118",
"r119",
"r120",
"r121",
"r122",
"r126",
"r128",
"r130",
"r131",
"r132",
"r135",
"r136",
"r401",
"r402",
"r467",
"r485"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Loss per share attributable to shareholders \u2013 basic and diluted (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r133",
"r134"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"auth_ref": [
"r410"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Net effect of foreign currency translation"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r44"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": 0.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
},
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": 2.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued payroll"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Share-Based Payment Arrangement, Option [Member]"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT):"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r66",
"r67",
"r68",
"r113",
"r114",
"r115",
"r117",
"r123",
"r125",
"r138",
"r202",
"r300",
"r302",
"r363",
"r364",
"r365",
"r377",
"r378",
"r400",
"r411",
"r412",
"r413",
"r414",
"r415",
"r416",
"r435",
"r491",
"r492",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityMethodInvestments": {
"auth_ref": [
"r14",
"r166",
"r198"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
"label": "Investment in South Korean joint venture"
}
}
},
"localname": "EquityMethodInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquityMethodInvestmentsPolicy": {
"auth_ref": [
"r87",
"r200",
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
"label": "Equity Method Investments [Policy Text Block]"
}
}
},
"localname": "EquityMethodInvestmentsPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ExtinguishmentOfDebtAmount": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Gross amount of debt extinguished.",
"label": "us-gaap_ExtinguishmentOfDebtAmount",
"terseLabel": "Extinguishment of Debt, Amount"
}
}
},
"localname": "ExtinguishmentOfDebtAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueOfFinancialInstrumentsPolicy": {
"auth_ref": [
"r404",
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
"label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
}
}
},
"localname": "FairValueOfFinancialInstrumentsPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"auth_ref": [
"r220",
"r221",
"r224",
"r225",
"r455",
"r456"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by major type or class of finite-lived intangible assets.",
"label": "Finite-Lived Intangible Assets by Major Class [Axis]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"auth_ref": [
"r220",
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
"label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
"auth_ref": [
"r418"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
"label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
}
}
},
"localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_GrantsReceivable": {
"auth_ref": [
"r24"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
"label": "us-gaap_GrantsReceivable",
"terseLabel": "Grants Receivable"
}
}
},
"localname": "GrantsReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r75",
"r108",
"r165",
"r171",
"r175",
"r178",
"r181",
"r201",
"r247",
"r248",
"r249",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r409"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "us-gaap_GrossProfit",
"totalLabel": "Gross profit"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
"auth_ref": [
"r93",
"r227",
"r230"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
"label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse",
"terseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
}
}
},
"localname": "ImpairmentOfLongLivedAssetsHeldForUse",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
"auth_ref": [
"r226",
"r233"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
"label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
}
}
},
"localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeLossFromEquityMethodInvestments": {
"auth_ref": [
"r70",
"r93",
"r162",
"r198",
"r463",
"r481"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
"label": "us-gaap_IncomeLossFromEquityMethodInvestments",
"negatedLabel": "Loss on investment in South Korean joint venture",
"terseLabel": "Income (Loss) from Equity Method Investments"
}
}
},
"localname": "IncomeLossFromEquityMethodInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r231",
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxPolicyTextBlock": {
"auth_ref": [
"r65",
"r370",
"r371",
"r373",
"r374",
"r375",
"r376"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
"label": "Income Tax, Policy [Policy Text Block]"
}
}
},
"localname": "IncomeTaxPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxesPaid": {
"auth_ref": [
"r90",
"r97"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
"label": "Income taxes"
}
}
},
"localname": "IncomeTaxesPaid",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r92"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Accounts payable and accrued expenses",
"verboseLabel": "Accounts payable and accrued expenses"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r92"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
"negatedLabel": "Accounts receivable"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
"auth_ref": [
"r92",
"r451"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
"verboseLabel": "Deferred revenue"
}
}
},
"localname": "IncreaseDecreaseInContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInventories": {
"auth_ref": [
"r92"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 13.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
"label": "us-gaap_IncreaseDecreaseInInventories",
"negatedLabel": "Inventories"
}
}
},
"localname": "IncreaseDecreaseInInventories",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Changes in assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r92"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 12.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"negatedLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"auth_ref": [
"r219",
"r222"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
"label": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
"terseLabel": "Intangible Assets, Net (Excluding Goodwill), Total"
}
}
},
"localname": "IntangibleAssetsNetExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r69",
"r159",
"r419",
"r422",
"r468"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "us-gaap_InterestExpense",
"negatedLabel": "Interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpenseDebt": {
"auth_ref": [
"r78",
"r283",
"r291",
"r294",
"r295"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
"label": "us-gaap_InterestExpenseDebt",
"terseLabel": "Interest Expense, Debt, Total"
}
}
},
"localname": "InterestExpenseDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r85",
"r89",
"r97"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPayableCurrent": {
"auth_ref": [
"r44"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": 2.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
},
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details": {
"order": 1.0,
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued interest"
}
}
},
"localname": "InterestPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryFinishedGoodsNetOfReserves": {
"auth_ref": [
"r32",
"r207"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details": {
"order": 0.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
"label": "Finished goods"
}
}
},
"localname": "InventoryFinishedGoodsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r6",
"r37",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventories, net of allowance",
"totalLabel": "Total"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryPolicyTextBlock": {
"auth_ref": [
"r9",
"r35",
"r104",
"r137",
"r204",
"r205",
"r208",
"r452"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
"label": "Inventory, Policy [Policy Text Block]"
}
}
},
"localname": "InventoryPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InventoryRawMaterialsNetOfReserves": {
"auth_ref": [
"r33",
"r207"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details": {
"order": 1.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
"label": "Raw material"
}
}
},
"localname": "InventoryRawMaterialsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryValuationReserves": {
"auth_ref": [
"r37",
"r206"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of valuation reserve for inventory.",
"label": "us-gaap_InventoryValuationReserves",
"terseLabel": "Inventory Valuation Reserves, Ending Balance"
}
}
},
"localname": "InventoryValuationReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
"auth_ref": [
"r93"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
"label": "Common stock issued in lieu of salary to officers and fees for services from vendors"
}
}
},
"localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseContractualTermAxis": {
"auth_ref": [
"r431"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by contractual term of lease arrangement.",
"label": "Lease Contractual Term [Axis]"
}
}
},
"localname": "LeaseContractualTermAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_LeaseContractualTermDomain": {
"auth_ref": [
"r431"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual term of lease arrangement.",
"label": "Lease Contractual Term [Domain]"
}
}
},
"localname": "LeaseContractualTermDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_LesseeLeasesPolicyTextBlock": {
"auth_ref": [
"r428"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
"label": "Lessee, Leases [Policy Text Block]"
}
}
},
"localname": "LesseeLeasesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseDiscountRate": {
"auth_ref": [
"r430"
],
"lang": {
"en-us": {
"role": {
"documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
"label": "us-gaap_LesseeOperatingLeaseDiscountRate",
"terseLabel": "Lessee, Operating Lease, Discount Rate"
}
}
},
"localname": "LesseeOperatingLeaseDiscountRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r433"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
"label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Total"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseRenewalTerm": {
"auth_ref": [
"r429"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
"terseLabel": "Lessee, Operating Lease, Renewal Term (Year)"
}
}
},
"localname": "LesseeOperatingLeaseRenewalTerm",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r43",
"r108",
"r173",
"r201",
"r247",
"r248",
"r249",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r387",
"r393",
"r394",
"r409",
"r438",
"r439"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "us-gaap_Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r30",
"r108",
"r201",
"r409",
"r440",
"r461",
"r478"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "us-gaap_LiabilitiesAndStockholdersEquity",
"totalLabel": "Total liabilities and stockholders\u2019 equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r8",
"r45",
"r108",
"r201",
"r247",
"r248",
"r249",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r387",
"r393",
"r394",
"r409",
"r438",
"r439",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "us-gaap_LiabilitiesCurrent",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesNoncurrent": {
"auth_ref": [
"r10",
"r11",
"r12",
"r20",
"r21",
"r108",
"r201",
"r247",
"r248",
"r249",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r387",
"r393",
"r394",
"r409",
"r438",
"r439"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
"label": "us-gaap_LiabilitiesNoncurrent",
"totalLabel": "Total long-term liabilities"
}
}
},
"localname": "LiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesNoncurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Long-term liabilities:"
}
}
},
"localname": "LiabilitiesNoncurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCredit": {
"auth_ref": [
"r20",
"r459",
"r472"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
"label": "us-gaap_LineOfCredit",
"terseLabel": "Long-Term Line of Credit, Total"
}
}
},
"localname": "LineOfCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityAxis": {
"auth_ref": [
"r41",
"r107"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
"label": "Lender Name [Axis]"
}
}
},
"localname": "LineOfCreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityLenderDomain": {
"auth_ref": [
"r41",
"r107"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
"label": "Line of Credit Facility, Lender [Domain]"
}
}
},
"localname": "LineOfCreditFacilityLenderDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
"auth_ref": [
"r41"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
"label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity",
"terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
}
}
},
"localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r20",
"r276",
"r289",
"r292",
"r293",
"r459",
"r474"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
"label": "us-gaap_LongTermDebt",
"terseLabel": "Long-Term Debt, Total"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtCurrent": {
"auth_ref": [
"r42"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Debt obligations, net of discount and amortization (Note 4)"
}
}
},
"localname": "LongTermDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtNoncurrent": {
"auth_ref": [
"r20"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
"label": "Long-term debt, noncurrent",
"terseLabel": "Long-term debt"
}
}
},
"localname": "LongTermDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r47"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-Term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r47",
"r246"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-Term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_MinorityInterest": {
"auth_ref": [
"r51",
"r108",
"r201",
"r247",
"r252",
"r253",
"r254",
"r260",
"r261",
"r409",
"r460",
"r477"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
"label": "Non-controlling interest (Note 8)"
}
}
},
"localname": "MinorityInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MinorityInterestDisclosureTextBlock": {
"auth_ref": [
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
"label": "Noncontrolling Interest Disclosure [Text Block]"
}
}
},
"localname": "MinorityInterestDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
"label": "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners",
"terseLabel": "Percent"
}
}
},
"localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details"
],
"xbrltype": "percentItemType"
},
"us-gaap_MinorityInterestOwnershipPercentageByParent": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
"label": "us-gaap_MinorityInterestOwnershipPercentageByParent",
"terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent"
}
}
},
"localname": "MinorityInterestOwnershipPercentageByParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r88"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cash flows from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r88"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cash flows from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r88",
"r91",
"r94"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cash flows from operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r118",
"r119",
"r120",
"r121",
"r126",
"r127",
"r129",
"r132",
"r165",
"r171",
"r175",
"r178",
"r181"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"totalLabel": "Net loss attributable to common shareholders"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
"auth_ref": [
"r303",
"r385",
"r391"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
"label": "Clyra Medical securities offering"
}
}
},
"localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NoncontrollingInterestMember": {
"auth_ref": [
"r113",
"r114",
"r115",
"r302",
"r380"
],
"lang": {
"en-us": {
"role": {
"documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
"label": "Noncontrolling Interest [Member]"
}
}
},
"localname": "NoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_NotesPayableCurrent": {
"auth_ref": [
"r42"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
"label": "us-gaap_NotesPayableCurrent",
"terseLabel": "Notes payable"
}
}
},
"localname": "NotesPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NotesPayableOtherPayablesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A written promise to pay a note to a third party.",
"label": "Notes Payable, Other Payables [Member]"
}
}
},
"localname": "NotesPayableOtherPayablesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_NumberOfOperatingSegments": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
"label": "us-gaap_NumberOfOperatingSegments",
"terseLabel": "Number of Operating Segments"
}
}
},
"localname": "NumberOfOperatingSegments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-details-textual"
],
"xbrltype": "integerItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r165",
"r171",
"r175",
"r178",
"r181"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "blgo_ProfitLossIncludingDeemedDividendsForTheChangeAccountingForDerivativeLiability",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating loss",
"totalLabel": "Operating loss"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseExpense": {
"auth_ref": [
"r427"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of operating lease expense. Excludes sublease income.",
"label": "us-gaap_OperatingLeaseExpense",
"terseLabel": "Operating Lease, Expense"
}
}
},
"localname": "OperatingLeaseExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r426"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "us-gaap_OperatingLeaseLiabilityCurrent",
"verboseLabel": "Current portion of operating lease liability"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r426"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating lease liability, net of current portion"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r425"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Right of use operating lease, net of amortization",
"terseLabel": "Operating Lease, Right-of-Use Asset"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r432",
"r434"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_OperatingSegmentsMember": {
"auth_ref": [
"r170",
"r171",
"r172",
"r173",
"r175",
"r181"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Operating Segments [Member]"
}
}
},
"localname": "OperatingSegmentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"auth_ref": [
"r4",
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r15"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other non-current assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
"auth_ref": [
"r55"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Foreign currency translation",
"verboseLabel": "Foreign currency translation"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherIncomeAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other (expense) income:"
}
}
},
"localname": "OtherIncomeAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r79"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "blgo_ProfitLossIncludingDeemedDividendsForTheChangeAccountingForDerivativeLiability",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "us-gaap_OtherNonoperatingIncomeExpense",
"totalLabel": "Total other (expense) income:"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
"auth_ref": [
"r98",
"r99",
"r100"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
"label": "Fair value of warrants issued with convertible notes"
}
}
},
"localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PatentsMember": {
"auth_ref": [
"r379"
],
"lang": {
"en-us": {
"role": {
"documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
"label": "Patents [Member]"
}
}
},
"localname": "PatentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_PaymentsToAcquireInterestInJointVenture": {
"auth_ref": [
"r80"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.",
"label": "us-gaap_PaymentsToAcquireInterestInJointVenture",
"terseLabel": "Payments to Acquire Interest in Joint Venture"
}
}
},
"localname": "PaymentsToAcquireInterestInJointVenture",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireMachineryAndEquipment": {
"auth_ref": [
"r81"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for acquisition of machinery and equipment.",
"label": "us-gaap_PaymentsToAcquireMachineryAndEquipment",
"negatedLabel": "Purchase of equipment"
}
}
},
"localname": "PaymentsToAcquireMachineryAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PlanNameAxis": {
"auth_ref": [
"r330",
"r331",
"r332",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r350",
"r351",
"r353",
"r354",
"r357",
"r358",
"r359",
"r360",
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by plan name for share-based payment arrangement.",
"label": "Plan Name [Axis]"
}
}
},
"localname": "PlanNameAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_PlanNameDomain": {
"auth_ref": [
"r330",
"r331",
"r332",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r350",
"r351",
"r353",
"r354",
"r357",
"r358",
"r359",
"r360",
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan name for share-based payment arrangement.",
"label": "Plan Name [Domain]"
}
}
},
"localname": "PlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_PolicyTextBlockAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_PolicyTextBlockAbstract",
"terseLabel": "Accounting Policies"
}
}
},
"localname": "PolicyTextBlockAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r22",
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Convertible Preferred Stock, Par Value (in dollars per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r22"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Convertible Preferred Stock, Shares Authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r22",
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Convertible Preferred Stock, Shares Issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r22"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Convertible Preferred Stock, Shares Outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r22",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at June 30, 2022 and December 31, 2021"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r38"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid expenses and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseNoncurrent": {
"auth_ref": [
"r15"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
"label": "Clyra Medical prepaid marketing (Note 8)"
}
}
},
"localname": "PrepaidExpenseNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromConvertibleDebt": {
"auth_ref": [
"r83"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
"label": "Proceeds Clyra Medical convertible note"
}
}
},
"localname": "ProceedsFromConvertibleDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r82"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from sales of common stock",
"terseLabel": "Proceeds from Issuance of Common Stock"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfDebt": {
"auth_ref": [
"r83"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
"label": "us-gaap_ProceedsFromIssuanceOfDebt",
"terseLabel": "Proceeds from Issuance of Debt"
}
}
},
"localname": "ProceedsFromIssuanceOfDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromLinesOfCredit": {
"auth_ref": [
"r83",
"r107"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
"label": "us-gaap_ProceedsFromLinesOfCredit",
"terseLabel": "Proceeds from Lines of Credit, Total"
}
}
},
"localname": "ProceedsFromLinesOfCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProductMember": {
"auth_ref": [
"r320"
],
"lang": {
"en-us": {
"role": {
"documentation": "Article or substance produced by nature, labor or machinery.",
"label": "Product [Member]"
}
}
},
"localname": "ProductMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProfitLoss": {
"auth_ref": [
"r3",
"r60",
"r62",
"r68",
"r86",
"r108",
"r116",
"r124",
"r125",
"r165",
"r171",
"r175",
"r178",
"r181",
"r201",
"r247",
"r248",
"r249",
"r252",
"r253",
"r254",
"r256",
"r258",
"r260",
"r261",
"r382",
"r389",
"r390",
"r397",
"r398",
"r402",
"r409",
"r469"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
"label": "Net loss",
"terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
}
}
},
"localname": "ProfitLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r229",
"r440",
"r470",
"r479"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 4.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Equipment and leasehold improvements, net of depreciation"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReceivablesPolicyTextBlock": {
"auth_ref": [
"r192",
"r195",
"r196",
"r197"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
"label": "Receivable [Policy Text Block]"
}
}
},
"localname": "ReceivablesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfLinesOfCredit": {
"auth_ref": [
"r84",
"r107"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
"label": "us-gaap_RepaymentsOfLinesOfCredit",
"negatedLabel": "Payment of Clyra Medical debt obligations",
"terseLabel": "Repayments of Lines of Credit"
}
}
},
"localname": "RepaymentsOfLinesOfCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLongTermDebt": {
"auth_ref": [
"r84"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
"label": "us-gaap_RepaymentsOfLongTermDebt",
"negatedLabel": "Payment of debt obligations"
}
}
},
"localname": "RepaymentsOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r368",
"r453",
"r503"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and development",
"negatedLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r26",
"r302",
"r440",
"r476",
"r494",
"r496"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r113",
"r114",
"r115",
"r117",
"r123",
"r125",
"r202",
"r363",
"r364",
"r365",
"r377",
"r378",
"r400",
"r491",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"auth_ref": [
"r156",
"r157",
"r170",
"r176",
"r177",
"r184",
"r185",
"r187",
"r317",
"r318",
"r454"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
"label": "Revenue",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerMember": {
"auth_ref": [
"r146",
"r187"
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
"label": "Revenue from Contract with Customer Benchmark [Member]"
}
}
},
"localname": "RevenueFromContractWithCustomerMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
"auth_ref": [
"r105",
"r309",
"r310",
"r311",
"r312",
"r313",
"r314",
"r315",
"r316",
"r322"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for revenue from contract with customer.",
"label": "Revenue from Contract with Customer [Policy Text Block]"
}
}
},
"localname": "RevenueFromContractWithCustomerPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenuesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenues"
}
}
},
"localname": "RevenuesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_RevolvingCreditFacilityMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
"label": "Revolving Credit Facility [Member]"
}
}
},
"localname": "RevolvingCreditFacilityMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale of Stock [Domain]"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
"label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]"
}
}
},
"localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of cash and cash equivalents.",
"label": "Schedule of Cash and Cash Equivalents [Table Text Block]"
}
}
},
"localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDebtTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
"label": "Schedule of Debt [Table Text Block]"
}
}
},
"localname": "ScheduleOfDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"auth_ref": [
"r9",
"r34",
"r35",
"r36"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Schedule of Inventory, Current [Table Text Block]"
}
}
},
"localname": "ScheduleOfInventoryCurrentTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOtherOwnershipInterestsTextBlock": {
"auth_ref": [
"r304"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of other units or shares or classes of ownership in a partnership.",
"label": "Schedule of Other Ownership Interests [Table Text Block]"
}
}
},
"localname": "ScheduleOfOtherOwnershipInterestsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
"auth_ref": [
"r165",
"r168",
"r174",
"r217"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
"label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]"
}
}
},
"localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r334",
"r349",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r356"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
"auth_ref": [
"r305",
"r329"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
"label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
}
}
},
"localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-6-warrants-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
"auth_ref": [
"r144",
"r146",
"r147",
"r148",
"r406",
"r408"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
"label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]"
}
}
},
"localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SecurityDeposit": {
"auth_ref": [
"r15"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
"label": "us-gaap_SecurityDeposit",
"terseLabel": "Security Deposit"
}
}
},
"localname": "SecurityDeposit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SegmentDomain": {
"auth_ref": [
"r152",
"r156",
"r157",
"r158",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r166",
"r167",
"r170",
"r171",
"r172",
"r173",
"r175",
"r176",
"r177",
"r178",
"r179",
"r181",
"r187",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r236",
"r237",
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Segments [Domain]"
}
}
},
"localname": "SegmentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"auth_ref": [
"r152",
"r154",
"r155",
"r165",
"r169",
"r175",
"r179",
"r180",
"r181",
"r182",
"r184",
"r186",
"r187",
"r188"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
"label": "Segment Reporting Disclosure [Text Block]"
}
}
},
"localname": "SegmentReportingDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r77"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, general and administrative expenses"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
"label": "Selling, General and Administrative Expenses [Member]"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpensesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ServiceMember": {
"auth_ref": [
"r320"
],
"lang": {
"en-us": {
"role": {
"documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
"label": "Service [Member]"
}
}
},
"localname": "ServiceMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r92"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "us-gaap_ShareBasedCompensation",
"verboseLabel": "Stock option compensation expense"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"auth_ref": [
"r330"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
"verboseLabel": "Expected volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r360"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
"verboseLabel": "Risk free interest rate"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
"auth_ref": [
"r332"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
"auth_ref": [
"r342"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"negatedLabel": "Options expired (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r339"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Options granted (in shares)",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r335",
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"periodEndLabel": "Options outstanding, balance (in shares)",
"periodStartLabel": "Options outstanding, balance (in shares)",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r335",
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"periodEndLabel": "Weighted average exercise price per share, balance (in dollars per share)",
"periodStartLabel": "Weighted average exercise price per share, balance (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
"auth_ref": [
"r353"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Vested, aggregate intrinsic value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
"auth_ref": [
"r353"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Options Vested (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r353"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Vested, June 30, 2022 (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r330",
"r331",
"r332",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r350",
"r351",
"r353",
"r354",
"r357",
"r358",
"r359",
"r360",
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r342"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
"label": "Weighted average exercise price per share, Expired (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r339"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Weighted average exercise price per share, granted (in dollars per share)",
"terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
"auth_ref": [
"r333",
"r355",
"r356",
"r357",
"r358",
"r361",
"r366",
"r367"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
"label": "Share-Based Payment Arrangement [Policy Text Block]"
}
}
},
"localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SharePrice": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Price of a single share of a number of saleable stocks of a company.",
"label": "us-gaap_SharePrice",
"terseLabel": "Share Price (in dollars per share)"
}
}
},
"localname": "SharePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
"auth_ref": [
"r331"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r357"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)",
"verboseLabel": "Life in years (Year)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of non-vested options outstanding.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
"negatedLabel": "Options Non-vested (in shares)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
"label": "Weighted average exercise price per share, Non-vested (in dollars per share)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharesIssued": {
"auth_ref": [
"r300"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
"label": "us-gaap_SharesIssued",
"periodEndLabel": "Balance (in shares)",
"periodStartLabel": "Balance (in shares)"
}
}
},
"localname": "SharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SharesIssuedPricePerShare": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or per unit amount of equity securities issued.",
"label": "us-gaap_SharesIssuedPricePerShare",
"terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
}
}
},
"localname": "SharesIssuedPricePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "us-gaap_SharesOutstanding",
"terseLabel": "Shares, Outstanding (in shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r102",
"r112"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementBusinessSegmentsAxis": {
"auth_ref": [
"r2",
"r152",
"r156",
"r157",
"r158",
"r159",
"r160",
"r161",
"r162",
"r163",
"r164",
"r165",
"r166",
"r167",
"r170",
"r171",
"r172",
"r173",
"r175",
"r176",
"r177",
"r178",
"r179",
"r181",
"r187",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r232",
"r236",
"r237",
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by business segments.",
"label": "Segments [Axis]"
}
}
},
"localname": "StatementBusinessSegmentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r50",
"r66",
"r67",
"r68",
"r113",
"r114",
"r115",
"r117",
"r123",
"r125",
"r138",
"r202",
"r300",
"r302",
"r363",
"r364",
"r365",
"r377",
"r378",
"r400",
"r411",
"r412",
"r413",
"r414",
"r415",
"r416",
"r435",
"r491",
"r492",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables",
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r113",
"r114",
"r115",
"r138",
"r454"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization",
"http://biolargo.com/20220630/role/statement-note-1-business-and-organization-details-textual",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies",
"http://biolargo.com/20220630/role/statement-note-10-commitments-and-contingencies-details-textual",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-credit-concentration-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-inventory-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-stock-options-valuation-assumptions-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-cash-balances-details",
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-details-textual",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-schedule-of-debt-details",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-stock-options-details",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants-warrants-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-common-and-preferred-shares-outstanding-details",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-summary-of-accounts-payable-and-accrued-expenses-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-details-textual",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-segment-information-details",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables",
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
"auth_ref": [
"r49",
"r280",
"r300",
"r301",
"r302"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
"label": "Conversion of notes (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
"label": "Issuance of common stock for service (in shares)",
"terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesIssuedForServices",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r22",
"r23",
"r300",
"r302"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Sale of common stock for cash (in shares)",
"terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
"auth_ref": [
"r50",
"r300",
"r302"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
"label": "Conversion of notes"
}
}
},
"localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
"label": "Issuance of common stock for service",
"terseLabel": "Stock Issued During Period, Value, Issued for Services"
}
}
},
"localname": "StockIssuedDuringPeriodValueIssuedForServices",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r22",
"r23",
"r300",
"r302"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Sale of common stock for cash",
"terseLabel": "Stock Issued During Period, Value, New Issues"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r23",
"r28",
"r29",
"r108",
"r194",
"r201",
"r409",
"r440"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "us-gaap_StockholdersEquity",
"totalLabel": "Total BioLargo Inc. and subsidiaries stockholders\u2019 equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r0",
"r1",
"r67",
"r108",
"r113",
"r114",
"r115",
"r117",
"r123",
"r201",
"r202",
"r302",
"r363",
"r364",
"r365",
"r377",
"r378",
"r380",
"r381",
"r396",
"r400",
"r409",
"r411",
"r412",
"r416",
"r435",
"r492",
"r493"
],
"calculation": {
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
"label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"periodEndLabel": "Balance",
"periodStartLabel": "Balance",
"totalLabel": "Total stockholders\u2019 equity"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-balance-sheets-current-period-unaudited",
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r417",
"r442"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r417",
"r442"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r417",
"r442"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Domain]"
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventsTextBlock": {
"auth_ref": [
"r441",
"r443"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
"label": "Subsequent Events [Text Block]"
}
}
},
"localname": "SubsequentEventsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Sale of Stock [Axis]"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events",
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Supplemental disclosures of cash flow information"
}
}
},
"localname": "SupplementalCashFlowInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_TableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_TableTextBlock",
"terseLabel": "Notes Tables"
}
}
},
"localname": "TableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-tables",
"http://biolargo.com/20220630/role/statement-note-4-debt-obligations-tables",
"http://biolargo.com/20220630/role/statement-note-5-sharebased-compensation-tables",
"http://biolargo.com/20220630/role/statement-note-6-warrants-tables",
"http://biolargo.com/20220630/role/statement-note-7-accounts-payable-and-accrued-expenses-tables",
"http://biolargo.com/20220630/role/statement-note-8-noncontrolling-interest-clyra-medical-tables",
"http://biolargo.com/20220630/role/statement-note-9-business-segment-information-tables"
],
"xbrltype": "stringItemType"
},
"us-gaap_UnrecognizedTaxBenefits": {
"auth_ref": [
"r369",
"r372"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unrecognized tax benefits.",
"label": "us-gaap_UnrecognizedTaxBenefits",
"terseLabel": "Unrecognized Tax Benefits, Ending Balance"
}
}
},
"localname": "UnrecognizedTaxBenefits",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r139",
"r140",
"r142",
"r143",
"r149",
"r150",
"r151"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_VariableInterestEntityOwnershipPercentage": {
"auth_ref": [
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
"label": "us-gaap_VariableInterestEntityOwnershipPercentage",
"terseLabel": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage"
}
}
},
"localname": "VariableInterestEntityOwnershipPercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_WarrantsAndRightsOutstandingTerm": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_WarrantsAndRightsOutstandingTerm",
"terseLabel": "Warrants and Rights Outstanding, Term (Month)"
}
}
},
"localname": "WarrantsAndRightsOutstandingTerm",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-note-11-subsequent-events-details-textual",
"http://biolargo.com/20220630/role/statement-note-3-sale-of-stock-for-cash-details-textual",
"http://biolargo.com/20220630/role/statement-note-6-warrants-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r126",
"r132"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted average number of common shares outstanding: (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://biolargo.com/20220630/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 7
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(24))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(iii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(25))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(2)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r112": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(26))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "270",
"URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(10))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(j)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "26",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "34",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
},
"r188": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "280",
"URI": "https://asc.fasb.org/topic&trid=2134510"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(21))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.BB)",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.BB)",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r208": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "330",
"URI": "https://asc.fasb.org/topic&trid=2126998"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(23))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "((a)(1),(b))",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.CC)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(d))",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r245": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r296": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org/topic&trid=2208564"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 4.F)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "50",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r322": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "https://asc.fasb.org/topic&trid=49130388"
},
"r323": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "710",
"URI": "https://asc.fasb.org/topic&trid=2127225"
},
"r324": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "712",
"URI": "https://asc.fasb.org/topic&trid=2197446"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r328": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "715",
"URI": "https://asc.fasb.org/topic&trid=2235017"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(c))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.D.2.Q6)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
},
"r367": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "https://asc.fasb.org/topic&trid=2228938"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "10B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "15A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "38",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "5A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "4I",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "4J",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
},
"r399": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "810",
"URI": "https://asc.fasb.org/topic&trid=2197479"
},
"r4": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "https://asc.fasb.org/topic&trid=2122149"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a),20,24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "60",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
},
"r418": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "830",
"URI": "https://asc.fasb.org/topic&trid=2175825"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r443": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "855",
"URI": "https://asc.fasb.org/topic&trid=2122774"
},
"r444": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r450": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "330",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "340",
"Topic": "928",
"URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(13)(f))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(24))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(25))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(24))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(10))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(20))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(21))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(c)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-30)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r491": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r492": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 4))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r504": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r505": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r506": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r507": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r508": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(12))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(22))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(23))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.8)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "21D",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
}
},
"version": "2.1"
} |
